Cogent Biosciences
COGT · NASDAQ
$31.24+$1.23 (+4.10%)TodayMarket closed ·
Prev close $30.01
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 24.4% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- -$0.55
- Revenue estimate
- $666.67K
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.5807 | -$0.52 | +10.5% |
| Q1 FY26 | -$0.5516 | -$0.60 | −8.8% |
| Q4 FY25 | -$0.5252 | -$0.635 | −20.9% |
| Q3 FY25 | -$0.5382 | -$0.50 | +7.1% |
| Q2 FY25 | -$0.5985 | -$0.53 | +11.4% |
| Q1 FY25 | -$0.5968 | -$0.52 | +12.9% |
| Q4 FY24 | -$0.6041 | -$0.12 | +80.1% |
| Q3 FY24 | -$0.5772 | -$0.64 | −10.9% |
Earnings calls
- 44th Annual J.P. Morgan Healthcare Conference
- Special Call - Cogent Biosciences, Inc.
- Special Call - Cogent Biosciences, Inc.
- Citi's Biopharma Back to School Conference
- Special Call - Cogent Biosciences, Inc.
- 43rd Annual J.P. Morgan Healthcare Conference 2025
- Special Call - Cogent Biosciences, Inc.
- Special Call - Cogent Biosciences, Inc.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.